Endologix Receives IDE Approval for the EVAS2 Confirmatory Clinical Study

 

October 6, 2017—Endologix, Inc. announced that it has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to commence a confirmatory clinical study to evaluate the safety and effectiveness of the company's Nellix endovascular aneurysm sealing (EVAS) system for the treatment of infrarenal abdominal aortic aneurysms.

According to Endologix, the EVAS2 IDE multicenter safety and effectiveness confirmatory study will prospectively evaluate the refined indications for use and the Nellix Gen2 EVAS system. The study is approved to enroll up to 90 primary patients, with 1-year follow-up data required for the premarket approval application.

Nellix, which is designed to seal the entire aneurysm, was developed as an alternative treatment approach to traditional endovascular aneurysm repair devices. The company continues to estimate that the device will receive FDA premarket approval in 2020.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.